Brean Murray Carret & Co. Downgrades Allos Therapeutics (ALTH) to Hold; Adding More Color To Spectrum (SPPI)

Brean Murray Carret & Co. downgraded Allos Therapeutics (NASDAQ: ALTH) from Buy to Hold.

Analyst, Brian Skorney, said, "The boards of directors for both Spectrum (Nasdaq: SPPI) and Allos have entered into a definitive acquisition agreement. We believe Spectrum is getting Allos for a 'song' as a result of desperation following the disappointing launch of Folotyn and the failed merger with AMAG last year."

Skorney sees Allos as a good strategic fit and thinks the stock reflects a good chance the merger goes through (not much upside investment from here).

For an analyst ratings summary and ratings history on Allos Therapeutics click here. For more ratings news on Allos Therapeutics click here.

Shares of Allos Therapeutics closed at $1.81 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Silver Lake In Talks To Buy Workday, Sources Say - Reuters
• Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform